Regulatory Submission in Europe in Absence of Reference product [Regulatives / Guidelines]

posted by dshah  – India/United Kingdom, 2021-03-23 10:51 (734 d 09:17 ago) – Posting: # 22290
Views: 6,626

Hi Abhay Patil!
In absence of Innovator product in EU and UK market for FDC, you may have to do BE against individual drug substance innovator product. Please see Guideline on clinical development of fixed combination medicinal products.
Regards,
Dshah

Complete thread:

UA Flag
Activity
 Admin contact
22,553 posts in 4,724 threads, 1,606 registered users;
14 visitors (1 registered, 13 guests [including 2 identified bots]).
Forum time: 21:08 CEST (Europe/Vienna)

Learning of many things
does not teach intelligence.    Heraclitus of Ephesus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5